Design, synthesis, and biological evaluation of novel nitric oxide releasing dehydroandrographolide derivatives.
Chin J Nat Med
; 16(10): 782-790, 2018 Oct.
Article
in En
| MEDLINE
| ID: mdl-30322612
ABSTRACT
A series of new hybrids of dehydroandrographolide (TAD), a biologically active natural product, bearing nitric oxide (NO)-releasing moieties were synthesized and designated as NO-donor dehydroandrographolide. The biological activities of target compounds were studied in human erythroleukemia K562 cells and breast cancer MCF-7 cells. Biological evaluation indicated that the most active compound I-5 produced high levels of NO and inhibited the proliferation of K562 (IC50 1.55 µmol·L-1) and MCF-7 (IC50 2.91 µmol·L-1) cells, which were more potent than the lead compound TAD and attenuated by an NO scavenger. In conclusion, I-5 is a novel hybrid with potent antitumor activity and may become a promising candidate for future intensive study.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Diterpenes
/
Antineoplastic Agents
/
Nitric Oxide
Limits:
Humans
Language:
En
Journal:
Chin J Nat Med
Year:
2018
Document type:
Article
Affiliation country:
China